Secukinumab Trial for Giant Cell Arteritis Brings Mixed but Useful Results

A major clinical trial testing the drug secukinumab in people with giant cell arteritis has produced results that are more nuanced than researchers had hoped, but still offer useful information for patients managing this condition. Giant cell arteritis, sometimes called temporal arteritis, is a form of vasculitis that inflames the large and medium arteries, most often those supplying the head and neck. Left untreated, it can cause vision loss, so getting inflammation under control quickly and keeping it controlled over time matters enormously to people living with the disease.

The trial, known as GCAptAIN, enrolled patients with new-onset or relapsing giant cell arteritis and randomly assigned them to receive secukinumab, an antibody that blocks a signaling protein called interleukin-17A, or a placebo. Everyone also received a tapering course of glucocorticoids, the steroid medications that remain the backbone of treatment but that carry real risks the longer and higher the dose. Patients getting secukinumab were able to taper off steroids faster, over 26 weeks instead of 52, while the placebo group stayed on the slower taper.

By week 52, about one in four patients on the higher secukinumab dose were in sustained remission, compared with roughly one in six on placebo. That difference did not reach statistical significance, meaning researchers cannot say with confidence that secukinumab caused the improvement. A lower dose of secukinumab performed similarly to placebo. However, patients on secukinumab experienced fewer serious side effects overall and somewhat fewer serious infections than those on placebo, even though they were also on steroids for a shorter stretch of time.

For patients, the takeaway is mixed but not discouraging. Secukinumab did not clearly outperform placebo at keeping disease in remission, but it allowed for a faster steroid taper without an apparent increase in flares or safety problems, which is meaningful given how much steroid related harm, including bone loss, diabetes, and cataracts, affects people with this disease over time. Researchers will likely use these findings to refine which patients might benefit most and how dosing strategies could be adjusted in future studies. Anyone currently being treated for giant cell arteritis should talk with their rheumatologist about what these results mean for their own steroid taper and treatment plan, since individual circumstances vary widely.